undamentalytics Newsletter

Perry Michael S: insider trades

Chief executive, Director at 3 companies we cover. 1 open-market purchase and 11 sales not made under a pre-set plan, reported from March 26, 2018 to August 20, 2026.

Would copying Perry Michael S’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. After their sales, the shares moved −18.5% against the index over 12 months on average (a negative figure means selling was the right call); 67% trailed it. None of their purchases could be priced, so there is no copy portfolio.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Perry Michael S: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 10 +2.5% −20.4% 60% 5 0.63 0.56 No reliable evidence
Sales, 12 months after the report 9 −18.5% −46.1% 67% 4 −0.50 0.65 No reliable evidence
Sales, 12 months after the trade 9 −16.8% −37.8% 56% 4 −0.36 0.74 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Avita Medical, Inc. RCEL Chief Executive Officer06September 11, 2020November 22, 2022
Arrowhead Pharmaceuticals, Inc. ARWR —05September 11, 2019August 20, 2026
Armata Pharmaceuticals, Inc. ARMP —10March 26, 2018March 26, 2018

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
August 20, 2026August 18, 2026 ARWR Sale $1,012,680 not yetnot yetnot yet
December 9, 2025December 5, 2025 ARWR Sale $991,738 −16.7%not yetnot yet
November 22, 2022November 21, 2022 RCEL Sale $1,077,000 +83.6%+36.0%+29.1%
February 25, 2022February 24, 2022 RCEL Sale $94,497 −33.6%+51.1%+52.8%
September 7, 2021September 1, 2021 RCEL Sale $232,030 −36.9%−59.1%−59.3%
June 4, 2021June 2, 2021 RCEL Sale $398,590 +9.1%−68.1%−66.5%
January 5, 2021January 4, 2021 ARWR Sale $304,360 −24.1%−46.1%−37.8%
September 16, 2020September 14, 2020 RCEL Sale $1,301,253 −45.8%−68.7%−64.4%
September 11, 2020September 10, 2020 RCEL Sale $707,581 −33.3%−64.4%−61.9%
May 13, 2020May 12, 2020 ARWR Sale $1,289,891 +1.3%+56.1%+47.5%
September 11, 2019September 9, 2019 ARWR Sale $5,440,000 +121.5%−2.9%+9.6%
March 26, 2018June 29, 2017 ARMP Purchase $200,002 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Perry Michael S traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.